Medical Advocates
Abacavir (Ziagen)
 
Journal Citations: Adverse Events

Agranulocytosis
 Fanconi's  Syndrome
 Hypersensitivity
 Metabolic Changes: General




 
Abacavir Journal Citations Main New/Newsworthy   Home Page    
Last Updated:  November 06, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 Notice: ABC/3TC/ZDV data are indexed on the Trizavir Web
Agranulocytosis
       
  FULL-TEXT ARTICLE
 Agranulocytosis induced by abacavir.
 Tikhomirov V, Namek J, Hindes R, et al
AIDS. 13(11):1420, July 30, 1999.
 Paper
Fanconi's  Syndrome
       
  Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus
in a patient with acquired immunodeficiency syndrome.
 Ahmad M. 
J Postgrad Med. 2006 Oct-Dec;52(4):296-7.
 Abstract
Hypersensitivity
 
 
A WEEK-IN-REVIEW FEATURED REPORT
Current trends in screening across ethnicities for hypersensitivity to abacavir.
 Rodriguez-Nóvoa S, Soriano V. 
Pharmacogenomics. 2008 Oct;9(10):1531-41.
 Abstract
 
First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in
North America.
Young B, Squires K, Patel P, et al
AIDS. 2008 Aug 20;22(13):1673-5
 Abstract
 
Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to
clinical utility.
 Hughes AR, Spreen WR, Mosteller M, et al
Pharmacogenomics J. 2008 Mar 11
 Abstract
 
Abacavir Hypersensitivity Reaction: an Update (March) (CE).
 Hughes CA, Foisy MM, Dewhurst N, et al 
Ann Pharmacother. 2008 Feb 26
 
A WEEK-IN-REVIEW FEATURED REPORT
 Association of Efavirenz Hypersusceptibility with Virologic Response in ACTG 368, a Randomized
Trial of Abacavir (ABC) in Combination with Efavirenz (EFV) and Indinavir (IDV) in HIV-Infected Subjects
with Prior Nucleoside Analog Experience.
 Demeter LM, Degruttola V, Lustgarten S, et al
 HIV Clin Trials. 2008 Jan-Feb;9(1):11-25
 Abstract
 
Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected
patients in Taiwan.
Sun HY, Hung CC, Lin PH, et al
 J  Antimicrob Chemother. 2007 Jul 12;
 Abstract
 
Immune responses to abacavir in antigen-presenting cells from hypersensitive patients.
Martin AM, Almeida CA, Cameron P, et al 
AIDS. 2007 Jun;21(10):1233-1244.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis
of sequence variation in HIV reverse transcriptase.
 Chui CK, Brumme ZL, Brumme CJ, et al 
Clin Infect Dis. 2007 Jun 1;44(11):1503-8.
 Abstract

Prospective Screening for Human Leukocyte Antigen-B*5701 Avoids Abacavir Hypersensitivity
Reaction in the Ethnically Mixed French HIV Population.
 Zucman D, de Truchis P, Majerholc C, et al 
J Acquir Immune Defic Syndr. 2007 Mar 8;
 Abstract

Identification of abacavir hypersensitivity reaction in health care claims data.
Nordstrom BL, Norman HS, Dube TJ, et al  
Pharmacoepidemiol Drug Saf. 2007 Jan 24
 Abstract
 
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
Gervasoni C, Vigano O, Grinelli E, et al
AIDS Patient Care STDS. 2007 Jan;21(1):1-3.
 Abstract
 
Abacavir hypersensitivity reaction in primary HIV infection.
 Stekler J, Maenza J, Stevens C
AIDS. 2006 Jun 12;20(9):1269-74.
 Abstract
 
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions
in the Western Australian HIV cohort study.
Rauch A, Nolan D, Martin A, et al
 Clin Infect Dis. 2006 Jul 1;43(1):99-102
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench
and back again.
Martin A, Nolan D, Almeida CA, Rauch A, Mallal S.
Pharmacogenomics. 2006 Jan;7(1):15-23.
Abstract
 
Clinical and immunogenetic correlates of abacavir hypersensitivity.
 Phillips EJ, Wong GA, Kaul R, et al  
AIDS. 2005 Jun 10;19(9):979-981.
 Abstract
 
[Abacavir Hypersensitivity Syndrome]
 Chirouze C, Hustache-Mathieu L, et al   
 Pathol Biol (Paris). 2004 Nov;52(9):529-33.
 Abstract
 
Unusual clinical presentation of hypersensitivity reaction to abacavir.
Aquilina C, Mularczyk M, Lucas F, Viraben R,
AIDS. 17(16):2403-2404, November 7, 2003.
Letter
Epidemiological risk factors for hypersensitivity reactions to abacavir.
Easterbrook PJ, Waters A, Murad S, et al  
HIV Med. 2003 Oct;4(4):321-324.
 Abstract
 
Enanthema as the first clinical manifestation of abacavir hypersensitivity reaction: a
case report.
 Lanzafame M, Trevenzoli M, Lattuada E, et al.
 Infez Med 2003 Mar;11(1):40-1
 Abstract
Abacavir hypersensitivity reaction.
Hewitt RG.
Clin Infect Dis 2002 Apr 15;34(8):1137-42
 Abstract

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity
to HIV-1reverse-transcriptase inhibitor abacavir.
 Mallal S, Nolan D, Witt C, et al.
 Lancet 2002 Mar 2;359(9308):727-32
 Abstract
 
Understanding drug hypersensitivity: what to look for when prescribing abacavir.
Hetherington S.
AIDS Read 2001 Dec;11(12):620-2
 Abstract

A near-fatal hypersensitivity reaction to abacavir: case report and literature review.
Shapiro M, Ward KM, Stern JJ.
AIDS Read 2001 Apr;11(4):222-6
 Abstract

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor
abacavir.
 Hetherington S, McGuirk S, Powell G, et al.
Clin Ther 2001 Oct;23(10):1603-14
 Abstract
 
FULL-TEXT ARTICLE
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug
regimens containing abacavir with or without nevirapine.
Wit F,Wood R, Horban A, et al
AIDS. 15(18):2423-2429, Dec 7, 2001.
 Paper
Metabolic Changes: General
       
  Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to
Didanosine and Stavudine vs. Abacavir and Lamivudine.
 Shlay JC, Visnegarwala F, Bartsch G,et al
 J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):147-155
 Abstract
 
Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with
additional nucleoside reverse transcriptase inhibitors.
 Venhoff N, Setzer B, Melkaoui K, Walker UA.
 Antivir Ther. 2007;12(7):1075-85.
 Abstract

Abacavir Journal Citations Main New/Newsworthy   Home Page    

Abacavir Journal Papers,  Abstracts, and Commentaries
 Adverse Events